

CITATION REPORT

List of articles citing

Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus

DOI: 10.1097/rhu.ob013e31829d5e50

Journal of Clinical Rheumatology, 2013, 19, 286-8.

Source: <https://exaly.com/paper-pdf/56383537/citation-report.pdf>

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
74	Hydroxychloroquine. <i>Reactions Weekly</i> , 2013 , 1479, 19-19	0	
73	Ciprofloxacin-Induced Syndrome of Inappropriate Antidiuretic Hormone; Anaphylactic Shock Due to Thrombolytic Administration; Hydroxychloroquine-Induced QT-Interval Prolongation; Complex Regional Pain Syndrome After Tetanus Toxoid Injection. <i>Hospital Pharmacy</i> , 2014 , 49, 329-33	1.1	4
72	Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. <i>Case Reports in Cardiology</i> , 2016 , 2016, 4626279	0.6	54
71	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. <i>Drug Safety</i> , 2018 , 41, 919-931	5.1	195
70	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020 , 11, 562777	5.6	7
69	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106143	14.3	51
68	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500	1	26
67	A systematic review of ECG findings in patients with COVID-19. <i>Indian Heart Journal</i> , 2020 , 72, 500-507	1.6	26
66	Correspondence on Qhydroxychloroquine, COVID-19 and the role of the rheumatologist by Graef. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
65	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. <i>PLoS ONE</i> , 2020 , 15, e0236778	3.7	14
64	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. <i>Pharmacogenomics and Personalized Medicine</i> , 2020 , 13, 531-542	2.1	5
63	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	10
62	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. <i>Respiratory Medicine</i> , 2020 , 106192	4.6	6
61	Hydroxychloroquine is protective to the heart, not harmful: a systematic review. <i>New Microbes and New Infections</i> , 2020 , 37, 100747	4.1	11
60	Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008662	6.4	200
59	QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. <i>Heart Rhythm</i> , 2020 , 17, 1425-1433	6.7	176
58	Advances in the relationship between coronavirus infection and cardiovascular diseases. <i>Biomedicine and Pharmacotherapy</i> , 2020 , 127, 110230	7.5	38

57	May Polyphenols Have a Role Against Coronavirus Infection? An Overview of Evidence. <i>Frontiers in Medicine</i> , 2020 , 7, 240	4.9	40
56	Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. <i>Journal of Diabetes</i> , 2020 , 12, 659-667	3.8	19
55	Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. <i>Circulation</i> , 2020 , 141, e906-e907	16.7	108
54	Effects of hydroxychloroquine treatment on QT interval. <i>Heart Rhythm</i> , 2020 , 17, 1930-1935	6.7	27
53	Hydroxychloroquine and COVID-19 - A narrative review. <i>Indian Journal of Tuberculosis</i> , 2020 , 67, S147-S154	1.6	5
52	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020 , 7, 502-519	6.6	7
51	Cardiac Arrhythmias in Autoimmune Diseases. <i>Circulation Journal</i> , 2020 , 84, 685-694	2.9	12
50	Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2623-2624	15.1	51
49	Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. <i>HeartRhythm Case Reports</i> , 2020 , 6, 241-243	1	24
48	The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. <i>Nature Medicine</i> , 2020 , 26, 808-809	50.5	207
47	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. <i>Clinical Infectious Diseases</i> , 2020 ,	11.6	432
46	COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. <i>Journal of Clinical Epidemiology</i> , 2020 , 123, 120-126	5.7	93
45	Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. <i>Heart Rhythm</i> , 2020 , 17, e231-e232	6.7	13
44	Managing ACS during COVID-19 infection: Do not follow the traditional route. <i>Indian Heart Journal</i> , 2020 , 72, 128-130	1.6	1
43	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa130	1	122
42	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 5-16	5.5	15
41	Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. <i>JACC: Clinical Electrophysiology</i> , 2021 , 7, 16-25	4.6	23
40	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13896	2.9	8

39	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. <i>Archives of Medical Research</i> , 2021 , 52, 261-269	6.6	6
38	Hydroxychloroquine: Not a Heart Breaker!. <i>Arthritis Care and Research</i> , 2021 , 73, 770-771	4.7	
37	Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. <i>International Journal of Cardiology</i> , 2021 , 324, 242-248	3.2	12
36	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. <i>Rheumatology International</i> , 2021 , 41, 257-273	3.6	0
35	Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes. <i>Toxicological Sciences</i> , 2021 , 180, 356-368	4.4	7
34	QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine. <i>Modern Rheumatology</i> , 2021 , 31, 1107-1112	3.3	3
33	QT Interval in Patients With COVID-19. <i>JAMA Cardiology</i> , 2021 , 6, 357	16.2	0
32	SARS-CoV-2 Therapy: Old Drugs as New Interventions. <i>Coronaviruses</i> , 2021 , 2, 142-150	1.5	1
31	Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Cardiovascular Development and Disease</i> , 2021 , 8,	4.2	
30	Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case. <i>Europace</i> , 2021 , 23, 1124-1133	3.9	2
29	Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. <i>European Journal of Pharmacology</i> , 2021 , 898, 173977	5.3	14
28	Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. <i>PLoS ONE</i> , 2021 , 16, e0251918	3.7	0
27	Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19. <i>Current Cardiology Reviews</i> , 2021 , 17, 319-327	2.4	2
26	Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia. <i>Lupus</i> , 2021 , 30, 1844-1848	2.6	0
25	Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study. <i>Clinical and Translational Science</i> , 2021 , 14, 1799-1809	4.9	0
24	Kombinierter Suizid: Methode nach Kusch und Kopfschuss – Ein Fallbericht. <i>Rechtsmedizin</i> , 1	0.6	
23	Risk assessment of drug-induced Long QT Syndrome for some COVID-19 repurposed drugs.		3
22	Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. 2020 ,		5

21	Chloroquine, but not hydroxychloroquine, prolongs the QT interval in a primary care population.		1
20	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19. 2020 ,		8
19	Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. <i>Indian Journal of Medical Research</i> , 2021 , 153, 219-226	2.9	1
18	The impact of hydroxychloroquine and azithromycin on the corrected qt interval in patients with the novel Coronavirus disease 2019. <i>Revista Da Associação Médica Brasileira</i> , 2021 , 67, 979-984	1.4	0
17	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2151-2160	9.5	2
16	I. Cloroquina / hidroxicloroquina y azitromicina. Revisi3n narrativa de seguridad. 2020 , 2, 71-82		
15	[QT Interval in Patients With COVID-19]. <i>Kardiologiya</i> , 2020 , 60, 11-14	1.5	1
14	A Patient with COVID-19 Pneumonia Who Developed Ventricular Fibrillation during Treatment with Hydroxychloroquine, Azithromycin and Favipiravir. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2020 , 94, 600-603	0.1	
13	Management of COVID-19 in the Intensive Care Unit.. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1353, 81-89	3.6	
12	Antimicrobial agents and torsades de pointes. 2022 , 231-266		
11	Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine treated systemic lupus erythematosus patients.. <i>Rheumatology</i> , 2022 ,	3.9	0
10	DataSheet_1.pdf. 2020 ,		
9	DataSheet_2.pdf. 2020 ,		
8	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , 2022 , 15, 634	5.2	1
7	Deacetylation mechanism and potential reversal strategy of long QT syndrome on hERG K+ channel under hypoxia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022 , 1868, 166487	6.9	
6	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		0
5	Risk of Arrhythmia among New Users of Hydroxychloroquine in RA and SLE : A Population-based Study.		
4	Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study with 19-Year Follow-up.		0

- 3 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 6
- 2 Local Anesthetic Like Inhibition of the Cardiac Na⁺ Channel Nav1.5 by Chloroquine and Hydroxychloroquine. Volume 14, 353-365 0
- 1 Effects of hydroxychloroquine on atrial electrophysiology in in silico wild-type and PITX2^{+/-} atrial cardiomyocytes. 0